Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion type Assertion NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_head.
- NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion description "[Frequencies were in detail: acute myeloid leukemia (AML): 40 of 3,798, 1.1%; myelodysplastic syndromes (MDS): 6 of 3,375, 0.2%; myeloproliferative neoplasms (MPNs): 5 of 1,720, 0.3%; MDS/MPN: 0 of 210; and chronic myelomonocytic leukemia: 0 of 447.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_provenance.
- NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion evidence source_evidence_literature NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_provenance.
- NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion SIO_000772 22162288 NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_provenance.
- NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion wasDerivedFrom befree-2016 NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_provenance.
- NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_assertion wasGeneratedBy ECO_0000203 NP946142.RA9ZZlTBP6LHf5hy7UZXhmaxQREkMuBSS2XN-umSgyhMA130_provenance.